VXRT - Vaxart, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.0000
-0.1300 (-6.10%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1300
Open2.0500
Bid1.9800 x 1200
Ask2.0000 x 800
Day's Range1.9700 - 2.1700
52 Week Range1.4400 - 7.6000
Volume327,015
Avg. Volume645,771
Market Cap14.282M
Beta (3Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-2.9050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2012-11-09
1y Target Est5.00
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Vaxart Announces Closing of Registered Direct Offering of Common Stock

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 per share. Total gross proceeds from the offering were $3.0 million, before deducting placement agent fees and estimated offering expenses. The securities described above were offered by Vaxart pursuant to a registration statement on Form S-3 (File No. 333-228910) previously filed with and subsequently declared effective by the Securities and Exchange Commission (SEC) on March 15, 2019.

  • ACCESSWIRE3 days ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • Business Wire3 days ago

    Vaxart Announces $3 Million Registered Direct Offering Priced At-the-Market

    Vaxart, Inc. (VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale in a registered direct offering priced at-the-market of 1,200,000 shares of the Vaxart’s common stock, at a purchase price of $2.50 per share, for aggregate gross proceeds of $3 million. H.C. Wainwright & Co. is acting as exclusive placement agent for the offering. The shares of common stock are being offered by Vaxart pursuant to a “shelf” registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC").

  • Business Wire3 days ago

    Vaxart Announces Initiation of Bivalent Norovirus Vaccine Phase 1b Clinical Trial

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b bivalent norovirus vaccine clinical trial. “The initiation of the bivalent norovirus vaccine Phase 1b trial marks a significant step towards our goal of developing a vaccine that can protect the most vulnerable patients from this highly infectious disease,” said Wouter Latour, M.D., chief executive officer of Vaxart.

  • Business Wirelast month

    Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

    Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019

  • Business Wire4 months ago

    Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Sean Tucker, Ph.D., chief scientific officer, will present summary data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at the World Vaccine and Immunotherapy Congress West Coast 2018, taking place from November 28-30, 2018 in San Diego, California. Vaxart received a $13.9 million contract from BARDA in September 2015 to support the advanced development of more effective influenza vaccines to ultimately improve seasonal and pandemic influenza preparedness.

  • Business Wire4 months ago

    Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update

    Start of Norovirus Vaccine Trials Delayed to 1H 2019 Due to Manufacturing Issue

  • InvestorPlace5 months ago

    Vaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain

    Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.

  • Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
    Zacks6 months ago

    Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

    Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Guardant Health and Vaxart

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Shares of Guardant Health made a staggering debut in the market on Thursday. The cancer detecting company closed up nearly 70% as it debuted on the NASDAQ. Shares of Vaxart Inc. also saw huge gains on news that its oral flu vaccine performed better than Sanofi's Fluzone in a phase 2 trial.

  • Business Wire6 months ago

    New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018. “These latest results show that our vaccine elicited a significant expansion of mucosal homing receptor α4β7+ (β7+) plasmablasts to approximately 60% of all activated B cells, while Fluzone only maintained baseline levels of 20%.

  • Business Wire7 months ago

    Vaxart Announces Second Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the second quarter ended June 30, 2018 and provided a corporate update.

  • Business Wire8 months ago

    Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the comprehensive results of the previously disclosed Phase 1 clinical trial with its norovirus oral tablet vaccine in the Journal of Clinical Investigation Insight. The paper by Leesun, Kim, et al., “Safety and immunogenicity of an oral tablet norovirus vaccine, a phase 1 randomized, placebo-controlled trial”, highlights the benign safety profile of the Vaxart vaccine and describes the generation of robust systemic and mucosal immune responses, including mucosal IgA, memory B cells, and serum blocking antibody titers (BT50), all potential correlates of protection.

  • Business Wire9 months ago

    Oral RSV Vaccine - Preclinical Data Published in Vaccine

    Vaxart, Inc. (VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced publication of the preclinical results of its oral F-protein based Respiratory Syncytial Virus (RSV-F) vaccine. The findings were published in the most recent online version of Vaccine (Joyce C. et al., “Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats”). As described in the article, the oral RSV-F vaccine candidate provided complete sterilizing protection against RSV infection in the cotton rat challenge model at the target dose.

  • Business Wire10 months ago

    Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today reported the topline results from a Phase 2 clinical trial evaluating the safety and efficacy of an antiviral teslexivir 5% gel dosed topically twice daily in 218 subjects for the treatment of condyloma, or anogenital warts. The primary efficacy endpoint was defined as complete clearance of baseline condyloma by week 16.

  • Business Wire10 months ago

    Vaxart to Present at the Jefferies 2018 Global Healthcare Conference

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Wouter Latour, M.D., president and chief executive officer of Vaxart, will present a company overview at the Jefferies 2018 Global Healthcare Conference on Friday, June 8, 2018, at 1:00 p.m. EST in New York. A live webcast of the presentation will be available by visiting the Investors section of Vaxart’s website at investors.vaxart.com. A replay of the webcast will be archived on Vaxart’s website for 30 days following the presentation.

  • Business Wire10 months ago

    Vaxart to Present at ASM Microbe 2018

    Vaxart, Inc. (VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo, Ph.D., lead scientist of Vaxart, will present data on the Phase 1 norovirus vaccine trial in a poster presentation at the American Society of Microbiology 2018, taking place from June 7-11, 2018 in Atlanta, Georgia.

  • Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?
    Simply Wall St.10 months ago

    Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?

    Measuring Vaxart Inc’s (NASDAQ:VXRT) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...

  • Business Wire10 months ago

    Vaxart Announces First Quarter 2018 Financial Results and Corporate Update

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the first quarter ended March 31, 2018 and provided a corporate update.

  • Business Wire11 months ago

    Vaxart Appoints Dr. David Taylor as Chief Medical Officer

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Taylor, M.D., as Chief Medical Officer.

  • Business Wire11 months ago

    Vaxart Announces $5 Million Inavir® Revenue Milestone

    Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir®, a single dose product licensed in Japan to prevent or treat influenza infection, exceeded ¥20 billion in the fiscal year 2017, triggering a $5 million milestone ...

  • Business Wire11 months ago

    Vaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations

    Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of Brant Biehn as Senior Vice President, Commercial Operations.

  • Business Wire11 months ago

    Vaxart to Present at Two Upcoming Medical Meetings

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that new preclinical data on its intranasal Chikungunya virus study will be highlighted in an oral presentation at the 28th European Congress of Clinical Microbiology and Infectious Diseases , taking place from April 21-24, 2018 in Madrid, ...

  • Business Wirelast year

    Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress

    Vaxart, Inc. , a clinical stage biotechnology company developing oral recombinant vaccines administered by tablet rather than by injection, today announced that the complete clinical dataset from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine will be highlighted in an oral presentation at the World Vaccine Congress , taking place from April 2-5, 2018 in Washington, D.C.